Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A 30 Day Study to Evaluate Efficacy and Safety of Pre-hospital vs. In-hospital Initiation of Ticagrelor Therapy in STEMI Patients Planned for Percutaneous Coronary Intervention (PCI) (ATLANTIC)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
AstraZeneca
ClinicalTrials.gov Identifier:
NCT01347580
First received: April 19, 2011
Last updated: December 17, 2013
Last verified: December 2013

April 19, 2011
December 17, 2013
September 2011
November 2013   (final data collection date for primary outcome measure)
  • Thrombolysis In Myocardial Infarction (TIMI) flow grade 3 of MI culprit vessel at initial angiography (co-primary endpoint) [ Time Frame: At initial angiography, pre PCI ] [ Designated as safety issue: No ]
  • ST-segment resolution up to pre PCI ≥70% (co-primary endpoint) [ Time Frame: Between baseline and PCI ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01347580 on ClinicalTrials.gov Archive Site
  • Percentage of patients with composite of death [ Time Frame: during the 30 days of treatment ] [ Designated as safety issue: No ]
  • Percentage of patients presenting an acute stent thrombosis episode [ Time Frame: during 30 days of treatment ] [ Designated as safety issue: No ]
  • The total number of patients with major life-threatening bleeding events [ Time Frame: within the first 48 hours and during 30 days of treatment ] [ Designated as safety issue: No ]
  • Total number of patients with other major bleeding events [ Time Frame: within the first 48 hours and during 30 days of treatment ] [ Designated as safety issue: No ]
  • Total number of patients with minor or major bleeding events [ Time Frame: within the first 48 hours and during 30 days of treatment ] [ Designated as safety issue: No ]
  • Percentage of patients with MI [ Time Frame: during the 30 days of treatment ] [ Designated as safety issue: No ]
  • Percentage of patients with urgent revascularization [ Time Frame: during the 30 days of treatment ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
A 30 Day Study to Evaluate Efficacy and Safety of Pre-hospital vs. In-hospital Initiation of Ticagrelor Therapy in STEMI Patients Planned for Percutaneous Coronary Intervention (PCI)
A 30 Day International, Randomized, Parallel-group, Double-blind, Placebo-controlled Phase IV Study to Evaluate Efficacy and Safety of Pre-hospital vs. In-hospital Initiation of Ticagrelor Therapy in STEMI Patients Planned for PCI.

The aim of this study is to determine whether initiation of ticagrelor as early as in the ambulance setting leads to a rapid reperfusion of the infarct-related artery therefore facilitating the Percutaneous Coronary Intervention (PCI) and optimizing the outcome for the patient.

The study will assess the efficacy and safety of pre-hospital compared to in-hospital administration of ticagrelor in co-administration with aspirin, on restoring the blood flow in the occluded heart artery and improving the myocardial perfusion in patients suffering from myocardial infarction and planned to have a PCI. Patients can be randomised in either one of the 2 arms:

re-hospital ticagrelor arm: Patients will receive a loading dose of 180 mg ticagrelor for the pre-hospital administration and placebo for in-hospital administration.

or In-hospital ticagrelor arm: Patients will receive a placebo for pre-hospital administration and 180 mg ticagrelor loading dose for in-hospital administration.

Patients are initially managed by ambulance physician/personnel in pre hospital settings. They are then transferred into a Catheterization room to undergo a PCI.

After the administration of the loading dose of ticagrelor (double blind), patients will continue on ticagrelor 90 mg bid and be followed in study for 30 days post randomisation.

Not Provided
Interventional
Phase 4
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
  • Myocardial Infarction
  • Segment Elevation Myocardial Infarction (STEMI)
  • Drug: Ticagrelor
    Oral Ticagrelor loading dose (180 mg) followed by matching placebo
  • Drug: Placebo
    Placebo followed by oral Ticagrelor loading dose (180 mg)
  • Experimental: Ticagrelor
    Loading dose of Ticagrelor (180 mg) followed by matching placebo. After the loading dose the patient will receive Ticagrelor (90 mg bid) for 30 days.
    Intervention: Drug: Ticagrelor
  • Experimental: Placebo
    Placebo followed by a loading dose of Ticagrelor (180 mg). After the loading dose the patient will receive Ticagrelor (90 mg bid) for 30 days.
    Intervention: Drug: Placebo

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
1874
November 2013
November 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Women must not be of child-bearing potential (1 year post-menopausal or surgically sterile).
  • Symptoms of acute MI of more than 30 min but less than 6 hours
  • New persistent ST-segment elevation ≥ 1 mm in two or more contiguous electrocardiogram (ECG) leads.

Exclusion Criteria:

  • Expected time to 1st PCI balloon inflation in the hospital, from the qualifying ECG is more than 120 minutes
  • Contraindication to ticagrelor (refer to SmPC)
  • Concomitant medication that may increase the risk of bleeding [e.g non steroidal anti-inflammatory drugs (NSAIDs), oral anticoagulant and / or fibrinolytics, planned or administered 24 hours before randomization]
  • Any of the following conditions in the absence of a functioning implanted pacemaker: known SSS, second or third degree AVB, or documented syncope of suspected bradycardic origin.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Algeria,   Australia,   Austria,   Canada,   Denmark,   France,   Germany,   Hungary,   Italy,   Netherlands,   Spain,   Sweden,   United Kingdom
 
NCT01347580
D5130L00006
No
AstraZeneca
AstraZeneca
Not Provided
Study Director: Dr Judith Hsia, MD AstraZeneca
Principal Investigator: Pr Gilles Montalescot Pitie Salpetriere Hospital
AstraZeneca
December 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP